Shares of Telix Pharmaceuticals Ltd. (TLX) are down approximately 60% from their all-time high of $30.36, recorded in February 2025, to trade around $12.00.
Australia-based Telix is a global, commercial-stage radiopharmaceutical company. It has two FDA-approved cancer imaging agents and a deep *theranostic pipeline targeting a range of high-unmet-need oncology indications (*Theranostics is a novel approach that refers to the pairing of a diagnostic and a therapeutic radiopharmaceutical to target the same biomarker for both imaging and treatment).
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.